Cagrilintide for Obesity Shows No Negative Impact on Heart Rhythm

Cagrilintide is a novel investigational drug being developed for the treatment of obesity. As part of its safety evaluation, it is critical to understand its potential effects on cardiac repolarisation, the electrical process that resets the heart after each beat, measured by the QTc interval. This study aimed to thoroughly assess whether cagrilintide causes any clinically significant prolongation of the QTc interval in healthy participants.

The study demonstrated that cagrilintide did not cause any clinically significant prolongation of the QTc interval. The maximum mean change from baseline for cagrilintide was well within established safety margins, and no participant experienced a QTc prolongation of >60 ms. The primary analysis confirmed a favorable cardiac safety profile. The upper bound of the 90% confidence interval for the largest mean difference in QTc between cagrilintide and placebo was consistently <10 ms, indicating no clinically relevant effect on cardiac repolarisation. In contrast, the positive control, moxifloxacin, successfully demonstrated a clear and expected QTc prolongation, validating the study's ability to detect such changes. No unexpected serious adverse cardiac events were reported in the cagrilintide treatment group.